BRABOURNE

Rpg Life Sciences Limited has informed the Exchange that the board of directors, at its meeting held on August 25, 2006 has appointed Mr. Arvind Vasudeva as additional director of the company. The board of directors has also appointed Mr. Arvind Vasudeva as managing director of the company for a period of five years from August 25, 2006.

Rpg Life Sciences Limited has submitted to the Exchange a copy of the notice of the AGM of the Company to be held on August 25, 2006. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Rpg Life Sciences Limited had informed the Exchange with reference to issue of 19,40,000 equity shares of Rs. 10/- each for cash at a premium of Rs. 148/- per share and 6,00,000 warrants on preferential basis. These securities have been allotted on March 31, 2006. The Company has now informed the Exchange that there has been no variation between projected utilizations of funds for objects as stated in the explanatory statement to the notice for the general meeting convened for issue of equity shares and warrants on preferential basis, and acutal utilization of funds.

Rpg Life Sciences Limited has informed the Exchange that Remuneration/ Compensation committee at its meeting held on August 04, 2006 has granted options aggregating 18000 equity shares, with exercise price fixed at Rs 95 per equity share (being price higher than the closing price on BSE on day prior to the date of the meeting). Further, these options shall vest one fifth on linier scale based on performance every year, after one year from the date of grant. As per rules of 2005 ESOP, option can be exercised any time within ten years from the respective date of vesting subject to other rules of

Rpg Life Sciences Limited has informed the Exchange that Remuneration/Compensation committee at its meeting held on July 31,2006 has granted options aggregating 17000 equity shares, with exercise price fixed at Rs 91 per equity share (being price higher than the closing price on BSE on day prior to the date of the meeting). Further, of these shares, an option for 15000 equity shares shall vest one fifth on linier scale based on performance every year after one year from the date of grant, while an option for 2000 shares shall vest one fifth every year after one year from the date of grant. As

Rpg Life Sciences Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company will remain closed from August 17, 2006 to August 25, 2006 (both days inclusive) for the purpose of 25% dividend and Annual General Meeting.

Rpg Life Sciences Limited has informed the Exchange that Mr. Rajendra A. Shah on the date of assuming office of director / officer on June 27, 2006 has acquired nil shares of Rpg Life Sciences Limited.

Rpg Life Sciences Limited has informed the Exchange that the board of directors at its meeting held on June 27, 2006 has appointed Mr. R.A. Shah as an alternate director to Mr. Dilip Sen, a director of the company.

Rpg Life Sciences Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on June 27, 2006 has recommended dividend of Rs.2.50 (25%) per share of face value of Rs. 10. This will absorb Rs. 410 including dividend tax.

Rpg Life Sciences Limited has submitted to the Exchange a copy of the minutes of the EGM held on March 17, 2006. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Rpg Life Sciences Limited has informed the Exchange that the stock option for 40,000 equity shares of face value of Rs10/- each granted to Mr. Murli Ramachandran, Managing Director, Stands Cancelled due to his resignation (effective from the close of working hours of March 31, 2006 ) before the date of vesting ( i.e october 19 , 2006).

Rpg Life Sciences Limited has informed the Exchange that the auditor's have conducted the limited review of the un-audited financial results for the quarter and nine months ended December 31, 2005 and found the same to be in order subject to certain observations. The auditor's observations are: The auditors are unable to comment on the extent of realisability of investments made aggregating to Rs.341,308 thousands in the shares and debentures of and loans and advances aggregating to Rs.766,890 thousands given to 'Instant Trading and Investment Company Ltd', a wholly owned subsidiary whose net

Rpg Life Sciences Limited has informed the Exchange that at the EGM held on March 17, 2006 the shareholders of the company have approved the issue of 20,00,000 Equity Shares of Rs.10/- each and 6,00,000 warrants, on preferential basis.

Rpg Life Sciences Limited has submitted to the Exchange a copy of the notice of the EGM to be held on March 17, 2006. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Rpg Life Sciences Limited has informed the Exchange that the Board of Directors, at its meeting held on February 20, 2006, has approved issue of up to 20,00,000 equity shares of face value of Rs.10/- each on preferential basis to several investors at a price calculated in accordance with SEBI Guidelines. The Board of Directors has also approved issue of 6,00,000 warrants (each warrant carrying a right to apply for and be allotted one equity share of face value of Rs.10/- each) to one of the promoters companies at the same price at which equity shares would be issued on preferential basis to se

Rpg Life Sciences Limited has informed the Exchange that the Board of Directors at its meeting held on January 18, 2006 has appointed Mr. Dilip Sen as director of the Company in casual vacancy caused by death of the Company's director Mr. S. Ranji.

Rpg Life Sciences Limited has informed the Exchange that Mr. Dilip Sen who has been appointed as director of the Company on January 18, 2006, holds Nil shares of the Company.

Clarification of News : The press had reports on November 26, 2005 that investments of Rpg Life Sciences Limited would be hived off into a separate entity. The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Rpg Life Sciences Limited has vide its letter inter-alia stated, "We would like to inform you that the company, at present, is not aware about any such proposal and, therefore, we are unable to comment on the same

Rpg Life Sciences Limited has informed the Exchange that the auditor's have conducted the limited review of the un-audited financial results for the quarter and half year ended September 30, 2005 and found the same to be in order subject to certain observations. The auditor's observations are: The auditors are unable to comment on the extent of realisability of investments made aggregating to Rs.341,308 thousands in the shares and debentures of and loans and advances aggregating to Rs.766,890 thousands given to 'Instant Trading and Investment Company Ltd', a wholly owned subsidiary whose net w

Rpg Life Sciences Limited has informed the Exchange regarding the press release to be issued by the company on patent issued to the company for the active pharmaceutical ingredient Risperidone by U.S. patents and Trademarks office. A press release in this regard shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Rpg Life Sciences Limited has submitted to the Exchange a copy of the press release dated October 25, 2005 titled 'RPG LIfe Sciences Profit Surge Continues in Quarter 2'. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Rpg Life Sciences Limited has informed the Exchange that the Remuneration / Compensation of the Committee has on October 19, 2005 granted stock options to the employees under Employee Stock Option Scheme of the Company, for 1,07,150 shares at exercise price of Rs. 120 per share. The closing price on the BSE (being the exchange with highest trading) on October 18, 2005 was Rs. 119.40. The options shall vest, in accordance with the scheme of the Company, after one year from the date of grant. The employees who continue to be in employment or those who retire in normal course shall have time of 1

Rpg Life Sciences Limited has informed the Exchange that the auditor's have conducted the limited review of the unaudited financial results for the quarter ended June 30, 2005 and the details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Rpg Life Sciences Limited has informed the Exchange that the register of members and share transfer books of the Company will remain closed from September 12, 2005 to September 19, 2005 (both days inclusive) for the purpose of AGM of the Company on September 19, 2005.

Rpg Life Sciences Limited has submitted to the Exchange a copy of the revised notice convening the AGM of the Company on September 19, 2005. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Rpg Life Sciences Limited has informed the Exchange that Mr. P K Mohapatra has been appointed as an additional director of the Company by the BODs on July 28, 2005.

Rpg Life Sciences Limited has informed the Exchange that Mr. P K Mohapatra who has been appointed as an additional director of the Company on July 28, 2005, holds Nil shares of the Company.

Rpg Life Sciences Limited has informed the Exchange that the auditor's remarks on accounts for the year ended March 31, 2005 pertain to the company's investments in and loans and advances to a subsidiary, whose quoted investments have suffered diminution in market value of quoted investments on Gross basis. The net diminution is about 10% of the gross diminution. Though the diminution is considered temporary in nature, as a matter of abundant caution, the company carries a provision of Rs.5 crores.

Rpg Life Sciences Limited has informed the Exchange that in view of steep decline in international prices of Spironolactone and Vitamin B12 and very high cost of manufacture of Androstene Dione (an intermediate used in manufacture of Spironnolactone) and Vitamin B12 at the company's facility at Pimpri, Pune taken on lease from Hindustan Antibiotics Ltd. ("the said facility") the company has decided to close its operations at the said facility with immediate effect. The company incurred losses in operations at the said facility since inception. The closure of the operations thereat thus is like

Rpg Life Sciences Limited has informed the Exchange that Bespoke Finvest Limited have acquired 18,50,000 Shares aggregating to 14.88% of the total paid-up capital of RPG Life Sciences Limited on March 30, 2005. The mode of acquisition is Inter se transfer among promoters and the shareholding of Bespoke Finvest Limited after the said acquisition is 18,50,000 Shares aggregating to 14.88% of the total paid-up capital of RPG Life Sciences Limited.

Rpg Life Sciences Limited has informed the Exchange that Off-Shore India Ltd have sold 6,07,500 Equity Shares aggregating to 4.89% of the total paid-up capital of RPG Life Sciences Limited on March 30, 2005. The mode of sale is through Inter se transfer among promoters and the shareholding of Off-Shore India Ltd. after the said sale is 2,76,866 Equity Shares aggregating to 2.23% of the total paid-up capital of RPG Life Sciences Limited.

Rpg Life Sciences Limited has informed the Exchange regarding the sale of shares by OffShore India Limited and Jubilee Investments & Industries Limited and the purchase of share by Bespoke Finvest Limited. The details are follows: (1) Bespoke Finvest Limited has acquired 18,50,000 Equity Shares aggregating to 14.88% of the paid-up capital of RPG Life Sciences Limited on March 30, 2005. The mode of acquisition is Inter se transfer amongst promoters and the shareholding of Bespoke Finvest Limited after the said acquisition is 18,50,000 Equity Shares aggregating to 14.88% of the share capital of

Rpg Life Sciences Limited has informed the Exchange that Jubilee Investments & Industries Ltd have sold 10,00,000 Shares aggregating to 8.05% of the total paid-up capital of RPG Life Sciences Limited on March 30, 2005. The mode of sale is Inter se transfer among promoters and the shareholding of Jubilee Investments & Industries Ltd. after the said sale is 2,26,654 Shares aggregating to 1.82% of the total paid-up capital of RPG Life Sciences Limited.

RPG Life Sciences Limited has informed the Exchange that the auditors have conducted the limited review for the un-audited financial results for the quarter ended December 31, 2004 and the details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Bespoke Finvest Limited has informed the Exchange that they have acquired 18,50,000 Equity Shares aggregating to 14.88% of the paid-up capital of RPG Life Sciences Limited. The date of acquisition is March 30, 2005 and the mode of acquisition is Inter se transfer amongst promoters. The shareholding after the said acquisition of (i) Bespoke Finvest Limited by itself, is 18,50,000 Equity Shares aggregating to 14.88%, and (ii) Bespoke Finvest Limited together with Holding company is 18,50,100 Equity Shares aggregating to 14.89%, of the total paid-up capital of RPG Life Sciences Limited.

Jubilee Investments & Industries Ltd has informed the Exchange that they have sold 10,00,000 Equity Shares aggregating to 8.05% of the total paid-up capital of RPG Life Sciences Limited on March 30, 2005. The mode of sale is Inter se transfer and the shareholding of Jubilee Investments & Industries Ltd. after the said sale is 2,26,654 Equity Shares aggregating to 1.82% of the total paid-up capital of RPG Life Sciences Limited.

Off-Shore India Ltd has informed the Exchange that they have sold 6,07,500 Equity Shares aggregating to 4.89% of the total paid-up capital of RPG Life Sciences Limited on March 30, 2005. The mode of sale is through Inter se transfer and the shareholding of Off-Shore India Ltd. after the said sale is 2,76,866 Equity Shares aggregating to 2.23% of the total paid-up capital of RPG Life Sciences Limited.

RPG Life Sciences Limited has informed the Exchange that the auditors have conducted the limited review for the un-audited financial results for the three months (quarter) and six months (Half year) ended September 30, 2004 and the details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Rpg Life Sciences Limited has informed the Exchange that the auditors remark on the previous year's accounts pertaining to diminution in the value of investments will get addressed as and when capital market condition improves, as in the opinion of the management, the diminution is temporary in nature. As regards the remark on managerial remuneration, the government approval is awaited.

Rpg Life Sciences Limited ( RPGLS) has informed the Exchange that the Company has on September 28, 2004 announced its entry into the exclusive band of manufacturers globally of Vitamin B12 with its first sale of the product. RPGLS has exported 5 kgs. of USP grade Vitamin B12 to Mexico last week. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Clarification of News : The press had reports on September 17, 2004 that a leading unlisted stem cell research company is looking to acquire RPG Life Sciences Limited. The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. RPG Life Sciences Limited has vide its letter inter-alia stated, "The news appears to be report on the acquisition of the company's shares, of which the company is unaware, and therefore, are not able t